Axsome Therapeutics, Inc.

What they do

Axsome develops and commercializes innovative medicines for CNS conditions. Its marketed products are AUVELITY (dextromethorphan and bupropion) for major depressive disorder and, since April 2026, agitation associated with dementia due to Alzheimer's disease; SUNOSI (solriamfetol) for excessive daytime sleepiness in obstructive sleep apnea or narcolepsy; and SYMBRAVO (meloxicam-rizatriptan) for acute treatment of migraine. It also advances a pipeline including solriamfetol in ADHD, binge eating disorder, MDD with EDS symptoms and shift work disorder, and AXS-12 (reboxetine) for cataplexy in narcolepsy. It has no manufacturing operations described; commercialization is the primary source of revenue.

Revenue drivers

• AUVELITY — Net product sales for major depressive disorder and, since June 2026, agitation associated with dementia due to Alzheimer's disease; $180.3 million in Q2 2026, 51% year-over-year growth, and the largest product by revenue.
• SUNOSI — Net product revenue for excessive daytime sleepiness in obstructive sleep apnea or narcolepsy, including U.S. sales, royalties on out-licensed territories and milestone revenue; $35.8 million in Q2 2026, 20% year-over-year growth.
• SYMBRAVO — Net product sales for acute treatment of migraine with or without aura; $2.3 million in Q2 2026, launched in June 2025, and the smallest contributor.
• Pipeline and out-licensing — Solriamfetol and AXS-12 development programs; a portion of SUNOSI revenue is royalty revenue from Pharmanovia's licensed territory in Europe and parts of the Middle East and North Africa.

Recent performance

Second quarter 2026 total net product revenue was $218.4 million, up 46% from $150.0 million a year earlier. AUVELITY sales were $180.3 million (up 51%), SUNOSI revenue $35.8 million (up 20%), and SYMBRAVO sales $2.3 million. R&D expenses fell to $46.2 million from $49.5 million, while SG&A rose to $208.1 million from $130.3 million on AUVELITY commercialization and the Alzheimer's disease agitation launch. The net loss was $51.3 million, or $(0.99) per share, and cash and equivalents were $319.9 million at June 30, 2026.

Strategy

Management is focused on commercial execution, particularly growing AUVELITY in Alzheimer's disease agitation and major depressive disorder. The company expanded its sales force and launched AUVELITY for agitation associated with dementia due to Alzheimer's disease in June 2026. It continues to fund late-stage pipeline programs, including Phase 3 trials of solriamfetol in children and adolescents with ADHD (FOCUS-2, FOCUS-3), MDD with EDS symptoms (CLARITY), binge eating disorder (ENGAGE) and shift work disorder (SUSTAIN). An NDA for AXS-12 for cataplexy in narcolepsy has been accepted by the FDA with a PDUFA target action date of May 1, 2027.

Risks

• Product concentration — AUVELITY generated $180.3 million of $218.4 million in Q2 2026 net product revenue, so results depend heavily on that single product.
• Ongoing losses — The company reported a Q2 2026 net loss of $51.3 million and annual net losses each year from 2021 through 2025.
• Rising SG&A — SG&A expenses rose to $208.1 million in Q2 2026 from $130.3 million a year earlier, driven by commercialization and the AUVELITY Alzheimer's disease agitation launch.
• Pipeline and regulatory dependence — Future growth depends on pipeline programs such as AXS-12, whose NDA has a PDUFA target action date of May 1, 2027, and on solriamfetol Phase 3 trials that may not succeed.

Outlook

Management said it expects commercial momentum to build over the balance of the year, particularly with continued AUVELITY growth in Alzheimer's disease agitation and major depressive disorder, and that AXS-12's PDUFA target action date is May 1, 2027. The company believes its current cash is sufficient to fund anticipated operations into cash flow positivity based on the current operating plan. Q2 2026 cash was $319.9 million at June 30, 2026.